Agenda - PDCO agenda of the 27-30 January 2026 meeting
Submitted by Anonymous (not verified) on 27 January 2026 - 15:40
Agenda - PDCO agenda of the 27-30 January 2026 meeting
Scientific Advisory Group on Vaccines and Therapies for Infectious Diseases (SAG-V&ID)
Submitted by Anonymous (not verified) on 27 January 2026 - 15:36
Scientific Advisory Group on Vaccines and Therapies for Infectious Diseases (SAG-V&ID)
PSUSA/00011084/202503
Submitted by Anonymous (not verified) on 27 January 2026 - 15:07
PSUSA/00011084/202503
Human medicines European public assessment report (EPAR): Cetrotide, cetrorelix, Date of authorisation: 12/04/1999, Revision: 31, Status: Authorised
Submitted by Anonymous (not verified) on 27 January 2026 - 15:00
Human medicines European public assessment report (EPAR): Cetrotide, cetrorelix, Date of authorisation: 12/04/1999, Revision: 31, Status: Authorised
Avian influenza (bird flu)
Submitted by Anonymous (not verified) on 27 January 2026 - 15:00
Avian influenza (bird flu)
Human medicines European public assessment report (EPAR): Constella, linaclotide, Date of authorisation: 26/11/2012, Revision: 31, Status: Authorised
Submitted by Anonymous (not verified) on 27 January 2026 - 14:52
Human medicines European public assessment report (EPAR): Constella, linaclotide, Date of authorisation: 26/11/2012, Revision: 31, Status: Authorised
Human medicines European public assessment report (EPAR): Cimzia, certolizumab pegol, Date of authorisation: 01/10/2009, Revision: 40, Status: Authorised
Submitted by Anonymous (not verified) on 27 January 2026 - 14:45
Human medicines European public assessment report (EPAR): Cimzia, certolizumab pegol, Date of authorisation: 01/10/2009, Revision: 40, Status: Authorised
PSUSA/00001469/202505
Submitted by Anonymous (not verified) on 27 January 2026 - 14:09
PSUSA/00001469/202505
Human medicines European public assessment report (EPAR): Avastin, bevacizumab, Date of authorisation: 12/01/2005, Revision: 68, Status: Authorised
Submitted by Anonymous (not verified) on 27 January 2026 - 13:35
Human medicines European public assessment report (EPAR): Avastin, bevacizumab, Date of authorisation: 12/01/2005, Revision: 68, Status: Authorised
Quarterly System Demo - Q2 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 25 June 2026, 09:00 (CEST) to 25 June 2026, 12:30 (CEST)
Submitted by Anonymous (not verified) on 27 January 2026 - 13:30
Quarterly System Demo - Q2 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 25 June 2026, 09:00 (CEST) to 25 June 2026, 12:30 (CEST)